Excerpt from FDA report: (doesn't mean much to me - interpretation anyone?)
1.2. Conclusions on the Substantial Evidence of Effectiveness The placebo-controlled study ACP-2566-003 was an adequate and well-controlled study that supports approval of trofinetide for the treatment of children and adults with Rett syndrome. ACP-2566-003 was a multicenter study that provided reliable and statistically significant evidence that treatment with trofinetide for 3 months demonstrated benefit on the co-primary endpoints of the Rett Syndrome Behavior Questionnaire (RSBQ) and clinician rating of the Clinician Global Impression of Improvement (CGI-I). The study also demonstrated a statistically significant difference favoring trofinetide on the prespecified secondary endpoint of the Communication and Symbolic Behavior Scales Developmental Profile – Infant and Toddler – Social Composite Score (CSBS-DP-IT-SCS). This scale, developed as a screening tool to alert clinicians to potential communication deficits in infants and toddlers, is not fit for purpose for determining a treatment-related benefit in the complex concept of social reciprocity and communication ; however, the finding of a benefit on this endpoint in trofinetide Reference ID: 5139595 (b) (4) Clinical Review Michael A. Dimyan, MD NDA 217026 DAYBUE (Trofinetide) CDER Clinical Review Template 14 Version date: March 8, 2019, for all NDAs and BLAs patients is still supportive of overall effectiveness. Further confirmatory evidence of effectiveness was obtained in study NEU-2566-RETT-002, a multisite Phase 2 single-blind placebo run-in, randomized double-blind, placebo-controlled dose ranging clinical trial. The objective of NEU-2566-RETT-002 was to investigate the safety, tolerability, and pharmacokinetics of treatment with 3 different doses of oral trofinetide in girls ages 5 to 15 with Rett syndrome. A total of 82 subjects were enrolled and five outcome measures explored, but the primary support for effectiveness came from comparison of RSBQ and CGI-I in 24 placebo-treated subjects and 27 subjects receiving 200 mg/kg twice daily of trofinetide. Although formal statistical testing for efficacy was not prespecified, the least square means difference between trofinetide and placebo in RSBQ met nominal significance (p=0.042) as did CGI-I (P=0.029).
- Forums
- ASX - By Stock
- NEU
- Neuren AGM 30th May
Neuren AGM 30th May, page-23
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B |
Open | High | Low | Value | Volume |
$15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 125 | $16.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.20 | 1500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 125 | 16.150 |
1 | 650 | 16.110 |
1 | 500 | 16.100 |
2 | 510 | 16.050 |
1 | 662 | 16.040 |
Price($) | Vol. | No. |
---|---|---|
16.200 | 1500 | 1 |
16.290 | 10000 | 1 |
16.500 | 1250 | 2 |
16.600 | 100 | 1 |
16.750 | 1000 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |